Treatment planning for molecular targeted radionuclide therapy

Christine L. Hartmann Siantar, Kai Vetter, Gerald L Denardo, Sally J. DeNardo

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Molecular targeted radionuclide therapy promises to expand the usefulness of radiation to successfully treat widespread cancer. The unique properties of radioactive tags make it possible to plan treatments by predicting the radiation absorbed dose to both tumors and normal organs, using a pre-treatment test dose of radiopharmaceutical. This requires a combination of quantitative, high-resolution, radiation-detection hardware and computerized dose-estimation software, and would ideally include biological dose-response data in order to translate radiation absorbed dose into biological effects. Data derived from conventional (external beam) radiation therapy suggests that accurate assessment of the radiation absorbed dose in dose-limiting normal organs could substantially improve the observed clinical response for current agents used in a myeloablative regimen, enabling higher levels of tumor control at lower tumor-to-normal tissue therapeutic indices. Treatment planning based on current radiation detection and simulations technology is sufficient to impact on clinical response. The incorporation of new imaging methods, combined with patient-specific radiation transport simulations, promises to provide unprecedented levels of resolution and quantitative accuracy, which are likely to increase the impact of treatment planning in targeted radionuclide therapy.

Original languageEnglish (US)
Pages (from-to)267-280
Number of pages14
JournalCancer Biotherapy and Radiopharmaceuticals
Volume17
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Molecular Targeted Therapy
Radioisotopes
Radiation
Therapeutics
Neoplasms
Radiopharmaceuticals
Radiotherapy
Software
Technology

Keywords

  • Cancer
  • Dosimetry
  • Radiation detection
  • Radionuclide
  • Radiotherapy
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research

Cite this

Treatment planning for molecular targeted radionuclide therapy. / Hartmann Siantar, Christine L.; Vetter, Kai; Denardo, Gerald L; DeNardo, Sally J.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 17, No. 3, 2002, p. 267-280.

Research output: Contribution to journalReview article

Hartmann Siantar, Christine L. ; Vetter, Kai ; Denardo, Gerald L ; DeNardo, Sally J. / Treatment planning for molecular targeted radionuclide therapy. In: Cancer Biotherapy and Radiopharmaceuticals. 2002 ; Vol. 17, No. 3. pp. 267-280.
@article{e10d0ee9f8944a978cee124add5c1ef0,
title = "Treatment planning for molecular targeted radionuclide therapy",
abstract = "Molecular targeted radionuclide therapy promises to expand the usefulness of radiation to successfully treat widespread cancer. The unique properties of radioactive tags make it possible to plan treatments by predicting the radiation absorbed dose to both tumors and normal organs, using a pre-treatment test dose of radiopharmaceutical. This requires a combination of quantitative, high-resolution, radiation-detection hardware and computerized dose-estimation software, and would ideally include biological dose-response data in order to translate radiation absorbed dose into biological effects. Data derived from conventional (external beam) radiation therapy suggests that accurate assessment of the radiation absorbed dose in dose-limiting normal organs could substantially improve the observed clinical response for current agents used in a myeloablative regimen, enabling higher levels of tumor control at lower tumor-to-normal tissue therapeutic indices. Treatment planning based on current radiation detection and simulations technology is sufficient to impact on clinical response. The incorporation of new imaging methods, combined with patient-specific radiation transport simulations, promises to provide unprecedented levels of resolution and quantitative accuracy, which are likely to increase the impact of treatment planning in targeted radionuclide therapy.",
keywords = "Cancer, Dosimetry, Radiation detection, Radionuclide, Radiotherapy, Therapy",
author = "{Hartmann Siantar}, {Christine L.} and Kai Vetter and Denardo, {Gerald L} and DeNardo, {Sally J.}",
year = "2002",
doi = "10.1089/10849780260179233",
language = "English (US)",
volume = "17",
pages = "267--280",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment planning for molecular targeted radionuclide therapy

AU - Hartmann Siantar, Christine L.

AU - Vetter, Kai

AU - Denardo, Gerald L

AU - DeNardo, Sally J.

PY - 2002

Y1 - 2002

N2 - Molecular targeted radionuclide therapy promises to expand the usefulness of radiation to successfully treat widespread cancer. The unique properties of radioactive tags make it possible to plan treatments by predicting the radiation absorbed dose to both tumors and normal organs, using a pre-treatment test dose of radiopharmaceutical. This requires a combination of quantitative, high-resolution, radiation-detection hardware and computerized dose-estimation software, and would ideally include biological dose-response data in order to translate radiation absorbed dose into biological effects. Data derived from conventional (external beam) radiation therapy suggests that accurate assessment of the radiation absorbed dose in dose-limiting normal organs could substantially improve the observed clinical response for current agents used in a myeloablative regimen, enabling higher levels of tumor control at lower tumor-to-normal tissue therapeutic indices. Treatment planning based on current radiation detection and simulations technology is sufficient to impact on clinical response. The incorporation of new imaging methods, combined with patient-specific radiation transport simulations, promises to provide unprecedented levels of resolution and quantitative accuracy, which are likely to increase the impact of treatment planning in targeted radionuclide therapy.

AB - Molecular targeted radionuclide therapy promises to expand the usefulness of radiation to successfully treat widespread cancer. The unique properties of radioactive tags make it possible to plan treatments by predicting the radiation absorbed dose to both tumors and normal organs, using a pre-treatment test dose of radiopharmaceutical. This requires a combination of quantitative, high-resolution, radiation-detection hardware and computerized dose-estimation software, and would ideally include biological dose-response data in order to translate radiation absorbed dose into biological effects. Data derived from conventional (external beam) radiation therapy suggests that accurate assessment of the radiation absorbed dose in dose-limiting normal organs could substantially improve the observed clinical response for current agents used in a myeloablative regimen, enabling higher levels of tumor control at lower tumor-to-normal tissue therapeutic indices. Treatment planning based on current radiation detection and simulations technology is sufficient to impact on clinical response. The incorporation of new imaging methods, combined with patient-specific radiation transport simulations, promises to provide unprecedented levels of resolution and quantitative accuracy, which are likely to increase the impact of treatment planning in targeted radionuclide therapy.

KW - Cancer

KW - Dosimetry

KW - Radiation detection

KW - Radionuclide

KW - Radiotherapy

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0036062803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036062803&partnerID=8YFLogxK

U2 - 10.1089/10849780260179233

DO - 10.1089/10849780260179233

M3 - Review article

C2 - 12136519

AN - SCOPUS:0036062803

VL - 17

SP - 267

EP - 280

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 3

ER -